149765-15-1

Basic information

• Product Name: N-(4-CHLORO-7H-PYRROLO[2,3-D]PYRIMIDIN-2-YL)-2,2-DIMETHYLPROPIONAMIDE
• Synonyms: N-(4-CHLORO-7H-PYRROLO[2,3-D]PYRIMIDIN-2-YL)-2,2-DIMETHYLPROPIONAMIDE;PropanaMide, N-(4-chloro-7H-pyrrolo[2,3-d]pyriMidin-2-yl)-2,2-diMethyl-;N2-Pivaloyl-4-chloro-7H-pyrrolo[2,3-d]pyriMidine;N-(4-Chloro-7H-pyrrolo[2,3-d]pyriMidin-2-yl)-2,2-diMethyl propanaMide;N-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-2-yl)pivalamide;N-(4-Chloro-7H-pyrrolo[2,3-d]pyrimidin-2-yl)
• CAS NO: 149765-15-1
• Molecular Formula: C₁₁H₁₃ClN₄O
• Molecular Weight: 252.71
• Mol File: 149765-15-1.mol
• Article Data: 12

Chemical Properties

• Appearance: /
• Density: 1.381 g/cm³
• Refractive Index: 1.663
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: N-(4-CHLORO-7H-PYRROLO[2,3-D]PYRIMIDIN-2-YL)-2,2-DIMETHYLPROPIONAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-CHLORO-7H-PYRROLO[2,3-D]PYRIMIDIN-2-YL)-2,2-DIMETHYLPROPIONAMIDE(149765-15-1)
• EPA Substance Registry System: N-(4-CHLORO-7H-PYRROLO[2,3-D]PYRIMIDIN-2-YL)-2,2-DIMETHYLPROPIONAMIDE(149765-15-1)

Safety Data

• Hazardous Substances Data: 149765-15-1(Hazardous Substances Data)

Usage

General Description

N-(4-Chloro-7H-pyrrolo[2,3-d]pyrimidin-2-yl)-2,2-dimethylpropionamide is a chemical compound with potential applications in pharmaceutical research and drug development. It has a pyrrolopyrimidine core structure and contains a chloro group and a 2,2-dimethylpropionamide moiety. It may be used as a building block or a lead compound for the synthesis of new drugs targeting specific biological pathways. The compound's structural features make it an interesting candidate for designing new therapeutic agents, such as kinase inhibitors or potential anticancer drugs. Additionally, its unique chemical properties may offer opportunities for further exploration in medicinal chemistry and chemical biology. Further research and studies are necessary to explore the full potential and applications of N-(4-Chloro-7H-pyrrolo[2,3-d]pyrimidin-2-yl)-2,2-dimethylpropionamide in the pharmaceutical and biomedical fields.

InChI:InChI=1/C11H13ClN4O/c1-11(2,3)9(17)16-10-14-7(12)6-4-5-13-8(6)15-10/h4-5H,1-3H3,(H2,13,14,15,16,17)

Upstream product

• 3282-30-2 pivaloyl chloride 
• 7355-55-7 2-amino-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 
• 137281-08-4 N-(4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2-yl)pivalamide 
• 84955-31-7 4-chloro-7H-pyrrolo[2,3-d]pyrimidin-2-amine 

Downstream Products

• 149765-16-2 N-(4-chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-2-yl)-2,2-dimethyl-propionamide 
• 737792-27-7 4,5-dichloro-2-pivaloylamino-7H-pyrrolo[2,3-d]pyrimidine 
• 737792-28-8 5-bromo-4-chloro-2-pivaloylamino-7H-pyrrolo[2,3-d]pyrimidine 
• 909101-45-7 4-chloro-5-fluoro-2-pivaloylamino-7H-pyrrolo[2,3-d]pyrimidine 
• 1067137-28-3 4-chloro-7-[2-deoxy-3,5-di-O-(p-toluoyl)-β-D-erythro-pentofuranosyl]-5-fluoro-2-pivaloylamino-7H-pyrrolo[2,3-d]pyrimidine 
• 199938-73-3 chloro-7-[2-deoxy-3,5-di-O-(4-toluoyl)-β-D-erythro-pentofuranosyl]-5-iodo-2-pivaloylamino-7H-pyrrolo[2,3-d]pyrimidine 
• 737792-29-9 4,5-dichloro-7-[2-deoxy-3,5-di-O-(4-toluoyl)-β-D-erythro-pentofuranosyl]-2-pivaloylamino-7H-pyrrolo[2,3-d]pyrimidine 
• 737792-31-3 5-bromo-4-chloro-7-[2-deoxy-3,5-di-O-(4-toluoyl)-β-D-erythro-pentofuranosyl]-2-pivaloylamino-7H-pyrrolo[2,3-d]pyrimidine 
• 149765-17-3 diethyl N-<2-pivaloylamino-4-chloro<(pyrrolo<2,3-d>pyrimidin-5-yl)ethynyl>benzoyl>-L-glutamate 
• 502160-46-5 diethyl N-{4-[2-(2-pivaloylamino-4-ethylpyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-L-glutamate 
• 502160-41-0 diethyl N-{4-[2-(2-pivaloylamino-4-ethylpyrrolo[2,3-d]pyrimidin-5-yl)ethynyl]benzoyl}-L-glutamate 
• 199938-77-7 C₂₅H₂₂IN₅O₅ 
• 213823-30-4 C₃₈H₄₂N₆O₇ 
• 213823-33-7 N-[7-{(2R,4S,5R)-5-[Bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-4-hydroxy-tetrahydro-furan-2-yl}-5-cyano-2-(2,2-dimethyl-propionylamino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-2,2-dimethyl-propionamide 

Relevant articles and documents

Synthesis and Anti-HIV Activity of Guanine Modified Fluorinated Acyclic Nucleoside Phosphonate Derivatives

The preparation of an unprecedented series of nucleobase modified 3-fluoro-2-(phosphonomethoxy)propyl (FPMP) acyclic nucleosides in both their (R) and (S) enantiomerically pure forms is described. The synthesis focuses on a Mitsunobu alkylation reaction t

Synthesis of Galactosyl-Queuosine and Distribution of Hypermodified Q-Nucleosides in Mouse Tissues

Queuosine (Q) is a hypermodified RNA nucleoside that is found in tRNAHis, tRNAAsn, tRNATyr, and tRNAAsp. It is located at the wobble position of the tRNA anticodon loop, where it can interact with U as well as C bases located at the respective position of the corresponding mRNA codons. In tRNATyr and tRNAAsp of higher eukaryotes, including humans, the Q base is for yet unknown reasons further modified by the addition of a galactose and a mannose sugar, respectively. The reason for this additional modification, and how the sugar modification is orchestrated with Q formation and insertion, is unknown. Here, we report a total synthesis of the hypermodified nucleoside galactosyl-queuosine (galQ). The availability of the compound enabled us to study the absolute levels of the Q-family nucleosides in six different organs of newborn and adult mice, and also in human cytosolic tRNA. Our synthesis now paves the way to a more detailed analysis of the biological function of the Q-nucleoside family.

REAGENTS FOR REVERSIBLY TERMINATING PRIMER EXTENSION

This invention relates to the field of nucleic acid chemistry, more specifically to the field of compositions of matter that comprise triphosphates of modified 2'-deoxynucleosides and oligonucleotides that are formed when these are appended to the 3'-end of a primer, wherein said modifications comprise NH2 moiety attached to their 3'-hydroxyl group and a fluorescent species in a form of a tag affixed to the nucleobase via a linker that can be cleaved. Such compositions and their associated processes enable and improve the sequencing of oligonucleotides using a strategy of cyclic reversible termination, as outlined in US Patent 6,664,079. Most specifically, the invention concerns compositions of matter that are 5'-triphosphates of ribo- and 2'- deoxyribonucleosides carrying detectable tags and oligonucleotides that might be derived from them. The invention also concerns processes wherein a DNA polymerase, RNA polymerase, or reverse transcriptase synthesizes said oligonucleotides via addition of said triphosphates to a primer.